Lipoprotein(a): Emerging insights and therapeutics.

In another analysis from MESA, the conventional 30 mg/dL Lp(a) cutoff was associated with aortic valve calcifications in White participants but was only borderline significant in Black participants [71] .

also in 11,409 other papers

In the ORION-1 (Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol) trial, median Lp(a) levels decreased by 15–25 % from baseline in the single and 2-dose groups but did not reach statistical significance in any group as there was significant interindividual variation. 90 % of participants in the 300-mg two-dose group had lower Lp(a), and the 26 % median reduction at day 180 was similar to other PCSK9i trials [98] .

also in 111,027 other papers